@article{f729eec0dde542dabd502aaf636aa686,
title = "Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease",
keywords = "cardiovascular risk reduction, icosapent ethyl, REDUCE-IT, type 2 diabetes, VERTIS CV",
author = "Kim, {Joseph M.} and Bhatt, {Deepak L.} and Samuel Dagogo-Jack and Cherney, {David Z.I.} and Francesco Cosentino and McGuire, {Darren K.} and Pratley, {Richard E.} and Liu, {Chih Chin} and Cater, {Nilo B.} and Robert Frederich and Mancuso, {James P.} and Cannon, {Christopher P.}",
note = "Funding Information: Editorial support was provided by Kim Russell, PhD, of Engage Scientific Solutions (Horsham, UK) and was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and Pfizer Inc., New York, NY, USA. Some of these data were presented at the American Diabetes Association (ADA), 82nd Scientific Sessions, June 3‐7 March 2022, New Orleans, LA, USA. ",
year = "2023",
doi = "10.1111/dom.14965",
language = "English (US)",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
}